Substance / Medication

Sulfapyridine

Overview

Active Ingredient
sulfapyridine
RxNorm CUI
10188

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

3
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Management of pyoderma gangrenosum during pregnancy and breastfeeding: a systematic review.
Wanberg Lindsey J, Gorman Benjamin G, Theis-Mahon Nicole et al. · Int J Dermatol · 2025
PMID: 39086027Meta-Analysis
A Systematic Review of Mendelian Pyoderma Gangrenosum: Clinical and Genetic Characteristics in 120 Published Patients.
Norouzi-Barough Leyla, Biglari Sajjad, Sherkat Roya et al. · Exp Dermatol · 2025
PMID: 40329681Meta-Analysis
Outcomes and Risk Factors of Pyoderma Gangrenosum After Reduction Mammoplasty: A Systematic Review of the Literature and Case Report.
Dahy Asmaa Ali, Hassan Rasha Mohamad, Altramsy Ayman et al. · Aesthetic Plast Surg · 2025
PMID: 40389731Meta-AnalysisFull text (PMC)
Postsurgical Pyoderma Gangrenosum in Breast Surgery: An Updated Systematic Review, Takeaways, and the 6 Commandments.
Caddia Giorgio, Voulliaume Delphine, Dettori Laura et al. · Aesthet Surg J · 2025
PMID: 40417872Meta-Analysis
Pyoderma Gangrenosum in Pregnancy: A Systematic Review of Clinical Characteristics, Treatment Outcomes, and Maternofetal Implications.
Ball Gretchen D, Romanelli Sarah, Bodner Jacob M et al. · J Drugs Dermatol · 2025
PMID: 40627582Meta-Analysis
Treatments for Pyoderma Gangrenosum: A Systematic Review and Single-Arm Meta-Analysis of Systemic Therapies.
Kaur Manjit, Diaz Michael J, Anthony Michelle et al. · Int Wound J · 2025
PMID: 40740034Meta-AnalysisFull text (PMC)
Evaluation of Inclusion and Exclusion Criteria for Pyoderma Gangrenosum in Clinical Research: A Systematic Review.
Li Sara J, Xia Eric, Drake Lara et al. · Dermatology · 2024
PMID: 37879301Meta-Analysis
Association between pyoderma gangrenosum and autoimmune connective tissue disorders: A systematic review.
Tan Marcus G, Singh Nupur, Kirshen Carly et al. · Int J Dermatol · 2024
PMID: 38402537Meta-Analysis
Investigating historic cases of pyoderma gangrenosum in myelodysplastic syndrome and chronic myelomonocytic leukemia for possible VEXAS syndrome: A systematic review.
Croitoru David O, Huang Ryan S, McMullen Eric P et al. · J Am Acad Dermatol · 2024
PMID: 38906261Meta-Analysis
Use of biologic therapies in the management of pyoderma gangrenosum: a systematic review.
Zaman Michele, Martinez Rebeca, Mayur Omkar et al. · Arch Dermatol Res · 2024
PMID: 39158753Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sulfapyridine (substance)
SNOMED CT
27082000
UMLS CUI
C0038710
RxNorm CUI
10188

Clinical Data

This intervention maps to 4 entities in the Ltrl knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
3
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.